© 1995 American Heart Association, Inc.
Articles |
Hormonal Regulation of Serum Lipoprotein(a) Levels
Contrasting Effects of Growth Hormone and Insulin-Like Growth Factor–I
From the Metabolism Unit, Departments of Surgery (H.O.), Clinical Chemistry (L.B.), and Medicine (B.A.), and the Molecular Nutrition Unit, Center for Nutrition and Toxicology, Novum, Karolinska Institute at Huddinge University Hospital, Huddinge, and the Department of Internal Medicine (A.G.J., E.L., S.L.), Uppsala University Hospital, Uppsala, Sweden.
Correspondence to Bo Angelin, MD, Department of Medicine, Huddinge University Hospital, S-141 86 Huddinge, Sweden.
Abstract In response to treatment with growth hormone, serum levels of lipoprotein(a) increase, while those of LDL cholesterol decrease. To establish if increased levels of insulin-like growth factor–I may be of importance for these changes, we analyzed serum lipoprotein concentrations in 11 male patients with idiopathic osteoporosis who were treated with growth hormone (2 IU · m-2 · d-1) or insulin-like growth factor–I (80 µg · kg-1 · d-1) in a randomized, double-blind, crossover study. LDL cholesterol was reduced by 0.7 mmol/L (P<.01) during growth hormone treatment but was not affected when the same patients received insulin-like growth factor–I. In contrast, mean lipoprotein(a) levels increased from 519 to 571 mg/L (P<.03) in response to growth hormone but were reduced from 538 to 478 mg/L (P<.04) during treatment with insulin-like growth factor–I. These results indicate that growth hormone exerts its effects on lipoprotein metabolism independent of insulin-like growth factor–I. Furthermore, the results suggest that treatment with insulin-like growth factor–I may reduce lipoprotein(a) levels.
Key Words: growth hormone • insulin-like growth factor–I • lipoprotein
This article has been cited by other articles:
 |
|
 |
|
  A. Colao, D. Ferone, P. Marzullo, and G. Lombardi Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management Endocr. Rev., February 1, 2004; 25(1): 102 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lind, M. Rudling, S. Ericsson, H. Olivecrona, M. Eriksson, B. Borgstrom, G. Eggertsen, L. Berglund, and B. Angelin Growth Hormone Induces Low-Density Lipoprotein Clearance but not Bile Acid Synthesis in Humans Arterioscler. Thromb. Vasc. Biol., February 1, 2004; 24(2): 349 - 356. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. Sesmilo, W. P. Fairfield, L. Katznelson, K. Pulaski, P. U. Freda, V. Bonert, E. Dimaraki, S. Stavrou, M. L. Vance, D. Hayden, et al. Cardiovascular Risk Factors in Acromegaly before and after Normalization of Serum IGF-I Levels with the GH Antagonist Pegvisomant J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1692 - 1699. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Schuler-Luttmann, G. Monnig, A. Enbergs, H. Schulte, G. Breithardt, G. Assmann, S. Kerber, and A. von Eckardstein Insulin-Like Growth Factor-Binding Protein-3 Is Associated With the Presence and Extent of Coronary Arteriosclerosis Arterioscler. Thromb. Vasc. Biol., April 1, 2000; 20 (4): e10 - e15. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Tao, F. Acquati, S. M. Marcovina, and H. H. Hobbs Human Growth Hormone Increases Apo(a) Expression in Transgenic Mice Arterioscler. Thromb. Vasc. Biol., October 1, 1999; 19(10): 2439 - 2447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Paassilta, K. Kervinen, M. Linnaluoto, and Y. A. Kesaniemi Alcohol Withdrawal–Induced Change in Lipoprotein(a) : Association With the Growth Hormone/Insulin-like Growth Factor-I (IGF-I)/IGF-Binding Protein-1 (IGFBP-1) Axis Arterioscler. Thromb. Vasc. Biol., April 1, 1998; 18(4): 650 - 654. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. von Eckardstein, S. Kliesch, E. Nieschlag, A. Chirazi, G. Assmann, and H. M. Behre Suppression of Endogenous Testosterone in Young Men Increases Serum Levels of High Density Lipoprotein Subclass Lipoprotein A-I and Lipoprotein(a) J. Clin. Endocrinol. Metab., October 1, 1997; 82(10): 3367 - 3372. [Abstract] [Full Text] [PDF]
|
|